Potential of peptidergic nootropic therapy in developmental dysphasia in children
Zavadenko NN, Davydova LA, Suvorinova NY, Khondkaryan GS · 2019 · Zh Nevrol Psikhiatr Im S S Korsakova 119(11):47-53. PMID 31851172
What does this source report?
Randomized comparison with no drug treatment reported speech and parent-questionnaire changes over two months.
- Population and setting
- 54 children aged 3–4 with developmental dysphasia
- Evidence type
- Randomized trial
- Preparation
- See the original report; formulation details require verification.
- Source language
- Russian
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- No masking described; parental ratings and speech-development advice are relevant co-interventions.
- Pediatric clinical findings do not establish enhancement or safety in healthy adults.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Recorded source-check date: 2026-09-29. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Zavadenko NN, Davydova LA, Suvorinova NY, Khondkaryan GS. Potential of peptidergic nootropic therapy in developmental dysphasia in children Zh Nevrol Psikhiatr Im S S Korsakova 119(11):47-53. PMID 31851172 2019.
Molekul research summary: https://molekul.io/research/bio-31851172. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry